Orgenesis Inc (NASDAQ:ORGS) — Market Cap & Net Worth
Market Cap & Net Worth: Orgenesis Inc (ORGS)
Orgenesis Inc (NASDAQ:ORGS) has a market capitalization of $9.83 Million ($9.83 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27205 globally and #5628 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orgenesis Inc's stock price $1.95 by its total outstanding shares 5171310 (5.17 Million). Also see ORGS asset base for a full breakdown of the balance sheet.
Orgenesis Inc Market Cap History: 2025 to 2025
Orgenesis Inc's market capitalization history from 2025 to 2025. Data shows growth from $10.08 Million to $10.08 Million (0.00% CAGR). Also see Orgenesis Inc (ORGS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Orgenesis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orgenesis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ORGS stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ORGS by Market Capitalization
Companies near Orgenesis Inc in the global market cap rankings as of September 18, 2026. Review Orgenesis Inc (ORGS) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Orgenesis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Orgenesis Inc Historical Marketcap From 2025 to 2025
Between 2025 and today, Orgenesis Inc's market cap moved from $10.08 Million to $ 10.08 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.08 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 2nd, 2026 the market cap of Orgenesis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.83 Million USD |
| MoneyControl | $9.83 Million USD |
| MarketWatch | $9.83 Million USD |
| marketcap.company | $9.83 Million USD |
| Reuters | $9.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more